Portfolio Companies
Active portfolio companies
Abcuro
Abcuro is developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.
Affinia Therapeutics
Affinia is developing next-generation AAV gene therapies for rare and non-rare diseases.
Altido Therapeutics
Altido Therapeutics is clinical-stage company advancing a novel, cell-based therapy for treating patients with glioblastoma, the most prevalent and aggressive malignant brain tumor in adults.
Claris Bio
Claris is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases. is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases.
Crosstalk Bio
Crosstalk Bio is targeting tissue-resident immune cells to develop novel therapeutics for multiple autoimmune and inflammatory conditions.
Falcon Bio
Falcon Bio is developing novel therapies that target the key driver of cellular dysfunction in Friedreich's ataxia.
Harbor Health
Harbor Health is a Texas-based healthcare company that integrates care delivery and health insurance through an end-to-end care model.
InStride Health
Co-founded by clinicians from McLean Hospital, InStride offers technology-enhanced mental health treatment for adolescents.
Medair Therapeutics
Mediar is developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Modal Therapeutics
Modal is a discovery stage company pursuing therapeutics leveraging the TGFβ pathway.
Monimoi Therapeutics
Monimoi is pioneering the next-generation of therapies by widening the landscape of druggable targets to create durable treatments for cancer patients.
Nocion Therapeutics
Nocion is developing novel small molecule charged sodium channel blockers, “nocions,” that selectively affect actively firing nociceptors to treat neuroinflammatory indications.
Photys
Photys is developing a new class of bifunctional drugs for phosphorylation of kinases to treat cancer.
PreDICTA Biosciences
https://www.predictabiosciences.com/
A precision oncology company developing a whole-genome sequencing blood test to replace bone marrow biopsies for hematologic cancers.
Pykus
https://www.pykustherapeutics.com
Pykus is developing a novel intraocular polymer to replace the vitreous humor following retinal surgery.
QurAlis
QurAlis is developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.
Tuesday Health
Tuesday Health is a value-based, supportive care organization that is revolutionizing the approach to serious illness and end-of-life care.
Violet Therapeutics
https://www.linkedin.com/company/violet-therapeutics
Violet is leveraging first-in-class platforms to identify, map and mine the cellular connectome at scale.
Walden BioSciences
https://www.waldenbiosciences.com
Walden BioSciences is transforming the treatment of kidney disease by restoring or preserving podocyte function.
Exited portfolio companies
Adheron Therapeutics
Acquired by Roche (ADR: RHHBY) Oct. 2015
Monoclonal antibody (mAb) therapy for inflammatory diseases including rheumatoid arthritis.
Amolyt Pharma
Acquired by AstraZeneca (NASDAQ: AZN) Mar. 2024
Therapeutic peptides for rare endocrine and metabolic diseases.
Annovation BioPharma
Acquired by The Medicines Company (NASDAQ: MDCO) Jan. 2015
Novel precision anesthetics.
CoStim Pharmaceuticals
Acquired by Novartis (NYSE: NVS) Feb. 2014
Next-generation immuno-oncology drugs based on T-cell costimulatory targets.
LifeImage
Acquired by Intelerad Medical Systems Sep. 2022
Digital diagnostic image sharing platform.
Lysosomal Therapeutics
Acquired by Bial Biotech Oct. 2020
Novel personalized medicine platform to treat neurodegenerative diseases, targeting the mutant GBA1 gene.
QPID Health
Acquired by eviCore Healthcare Feb. 2016
EHR analytics software – extracting insight from information.
SeQure
Acquired by MaxCyte (NASDAQ: MXCT) Jan. 2025
Best-in-class technology to identify and manage the risks of off-target gene-editing agents.
Syntimmune
Acquired by Alexion (NASDAQ: ALXN) Nov. 2018
Advances the fight against autoimmune disease.
Tilos Therapeutics
Acquired by Merck (NYSE: MRK) June 2019
Anti-LAP antibodies: transforming the tumor microenvironment to treat cancer.
Verve Therapeutics
Acquired by Eli Lilly (NTSE: LLY) August 2025
Pioneering single-course gene editing medicines to treat cardiovascular disease.
IPOs
Akouos
IPO June 2020 (NASDAQ: AKUS); acquired by Lilly (NYSE: LLY) Dec. 2022
Precision genetic medicine company focused on inner ear disorders, including sensorineural hearing loss.
Denali Therapeutics
https://www.denalitherapeutics.com
IPO Dec. 2017 (NASDAQ: DNLI)
Defeating neurodegenerative diseases.
Editas Medicine
https://www.editasmedicine.com
IPO Feb. 2016 (NASDAQ: EDIT)
Unlocking the power and potential of CRISPR genome editing technology.
Keros Therapeutics
IPO April 2020 (NASDAQ: KROS)
Novel treatments for patients suffering from hematologic and musculoskeletal disorders.
Magenta
IPO June 2018 (NASDAQ: MGTA)
Revolutionizing stem cell transplant as the new treatment paradigm for immunologic and blood-based diseases.
Spero Therapeutics
https://www.sperotherapeutics.com
IPO Nov. 2017 (NASDAQ: SPRO)
Anti-infectives targeting Gram-negative bacteria.
Translate Bio
IPO June 2018 (NASDAQ:TBIO), acquired by Sanofi (NASDAQ: SNY) Sep. 2021
Developing messenger RNA (mRNA) therapies.
Verve Therapeutics
IPO June 2021 (NASDAQ:VERV)
Pioneering single-course gene editing medicines to treat cardiovascular disease.